文献速递冠心病心力衰竭与心肌病

罪犯病变位置与心源性休克PCI策略结局的关联

Association of Culprit Lesion Location With Outcomes of Culprit-Lesion-Only vs Immediate Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock: A Post Hoc Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2020-01-01

该研究为CULPRIT-SHOCK试验的事后分析,纳入685例多支病变合并急性心肌梗死及心源性休克患者,比较罪犯病变位于左主干或前降支近段与其他位置对仅处理罪犯病变PCI与立即多支PCI结局的影响。结果显示左主干或前降支近段组结局更差,且该组仅处理罪犯病变PCI在1年死亡风险上显著优于立即多支PCI,交互作用P=0.02。

要点

  • 左主干或前降支近段罪犯病变患者30天复合终点和1年死亡风险均更高。
  • 该亚组中仅处理罪犯病变PCI较立即多支PCI显著降低1年死亡风险。
  • 非左主干或前降支近段组两种PCI策略1年死亡风险无显著差异。

核心结论

  • 在多支病变合并心肌梗死及心源性休克患者中,罪犯病变位于左主干或前降支近段者结局更差。
  • 这类患者可能尤其受益于仅处理罪犯病变PCI并可选分期血运重建,但需进一步研究确认。

研究设计与样本

  • CULPRIT-SHOCK试验的事后分析,该试验为研究者发起的随机、开放标签临床试验。
  • 2013年4月至2017年4月在欧洲83个中心纳入多支病变、急性心肌梗死及心源性休克患者。
  • 患者随机接受仅处理罪犯病变PCI(可选分期血运重建)或立即多支PCI(1:1)。
  • 本分析按罪犯病变位于左主干或前降支近段与其他位置分层。
  • 研究人群中位年龄70岁(IQR 60-78),男性524例(76.4%)。

主要发现

  • 685例患者中,左主干或前降支近段组占33.4%,其他位置组占66.6%。
  • 左主干或前降支近段组30天复合终点(死亡或肾脏替代治疗)发生率为56.8%,其他位置组为47.5%(P=0.02)。
  • 左主干或前降支近段组1年死亡率为59.8%,其他位置组为50.1%(P=0.02)。

临床怎么用

  • 对于多支病变合并心肌梗死及心源性休克患者,应关注罪犯病变位置。
  • 左主干或前降支近段罪犯病变者,仅处理罪犯病变PCI并可选分期血运重建可能更优。

局限性

  • 为事后分析,结果需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Myocardial infarction with a culprit lesion located in the left main or proximal left anterior descending artery compared with other coronary segments is associated with more myocardium at risk and worse clinical outcomes. OBJECTIVE: To evaluate the association of culprit lesion location with outcomes of culprit-lesion-only percutaneous coronary intervention with optional staged revascularization vs immediate multivessel percutaneous coronary intervention in patients with multivessel disease, myocardial infarction, and cardiogenic shock. DESIGN, SETTING, AND PARTICIPANTS: Post hoc analysis of the Culprit Lesion Only Coronary Intervention vs Multivessel Coronary Intervention in Cardiogenic Shock (CULPRIT-SHOCK), an investigator-initiated randomized, open-label clinical trial. Patients with multivessel disease, acute myocardial infarction, and cardiogenic shock were enrolled at 83 European centers from April 2013 through April 2017. INTERVENTIONS: Patients were randomized to culprit-lesion-only percutaneous coronary intervention with optional staged revascularization or immediate multivessel percutaneous coronary intervention (1:1). For this analysis, patients were stratified by culprit lesion location in the left main or proximal left anterior descending artery group and other-culprit-lesion location group. MAIN OUTCOMES AND MEASURES: End points included a composite of death or kidney replacement therapy at 30 days and death at 1 year. RESULTS: The median age of the study population was 70 (interquartile range, 60-78 years) and 524 of the study participants were men (76.4%). Of the 685 patients, 33.4% constituted the left main or proximal left anterior descending artery group and 66.6% the other-culprit-lesion location group. The left main or proximal left anterior descending artery group had worse outcomes compared with the other-culprit-lesion location group (56.8% vs 47.5%; P = .02 for the composite end point at 30 days and 59.8% vs 50.1%; P = .02 for death at 1 year). In both groups, culprit-lesion-only vs immediate multivessel percutaneous coronary intervention was associated with a reduced risk of the composite end point at 30 days (49.1% vs 64.3% and 44.1% vs 50.9%; P for interaction = .27). At 1 year, culprit-lesion-only vs immediate multivessel percutaneous coronary intervention was associated with a significantly reduced risk of death in the left main or proximal left anterior descending artery but not the other-culprit-lesion location group (50.0% vs 69.6%; P = .003 and 49.8% vs 50.4%; P = .89; P for interaction = 0.02). CONCLUSIONS AND RELEVANCE: In patients with multivessel disease with myocardial infarction and cardiogenic shock, a culprit lesion located in the left main or proximal left anterior descending artery vs other coronary segments was associated with worse outcomes. These patients may especially benefit from culprit-lesion-only percutaneous coronary intervention with optional staged revascularization, although further investigation is needed to confirm this finding. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01927549.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Farhan S, Vogel B, Montalescot G, et al. Association of Culprit Lesion Location With Outcomes of Culprit-Lesion-Only vs Immediate Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2020. PMID: 32845312. doi:10.1001/jamacardio.2020.3377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。